An opinion article says the 2026 midterms and 2028 presidential election should focus on whether a president and associates can profit from the office. It cites Trump’s reported $2.2 billion in 2025 income and describes cryptocurrency holdings, a UAE-linked investment, licensing deals, and stock trades. The excerpt raises questions about conflicts but does not establish that a business investment caused a government decision or report a new investigation. It notes that conflict-of-interest laws for other federal officials do not apply to the president and that courts may have to resolve legal questions. No new fees, forms, compliance deadlines, or enforcement process are described; elections and any court proceedings are the next steps identified.
TLDR: The supplied opinion article connects Trump’s reported 2025 income to businesses and investors with interests in federal decisions, while raising ethical and legal questions. It describes no new policy, enforcement action, paperwork, or fee, and points to the 2026 and 2028 elections and possible court decisions as future tests.
A recent opinion article argues that the 2026 midterms and 2028 presidential election should test whether a president and his associates can profit from the presidency. It cites reported 2025 income of $2.2 billion for Donald Trump and says a substantial share came from people and entities with interests in presidential decisions. The excerpt does not provide a response from Trump or his administration to the specific financial examples it describes.
There is no new government policy or official rationale for a policy change in the material provided. The article’s argument is that elected officials have a legal and moral duty not to put personal interests ahead of constituents. That principle is presented as a safeguard against conflicts between public decisions and private gain.
The excerpt says laws that prevent conflicts of interest for other federal officials do not apply to the president. It also says the Supreme Court has defined corruption narrowly, requiring an explicit exchange of something valuable for an official act, and has granted the president broad immunity. The article argues that those legal limits do not settle the ethical question, while acknowledging that courts would have to decide whether certain alleged actions fall within a president’s official duties.
The reported income is linked in the excerpt to several business interests. It says $1.25 billion came from cryptocurrency interests, while the Securities and Exchange Commission announced it would not regulate cryptocurrency. It also describes a $500 million investment in World Liberty Financial by a firm controlled by the United Arab Emirates government, followed in close timing by a U.S.-UAE agreement involving exports of hundreds of thousands of computer chips used for artificial intelligence.
The excerpt says the chip agreement raised concerns about the UAE’s relationship with China and the possibility that China could obtain chips indirectly. It presents the timing of the investment and agreement as troubling, but the material provided does not establish that the investment caused the government decision. The distinction matters: a disclosed business connection and a policy decision can raise questions without, by themselves, proving an exchange or a violation of law.
Other sources of income described include royalties from sales of the $TRUMP memecoin and World Liberty products. The excerpt says purchasers of the coin lost money as its value fell, while Trump and partners earned transaction fees on purchases and sales. It further says these businesses were not regulated by a government agency. The material does not provide a total for those fees or identify a specific enforcement action.
The article also describes licensing of the Trump name to properties in Qatar and Saudi Arabia, countries with important U.S. relationships, and raises questions about stock trades. Its excerpt begins an example involving a purchase of up to $5 million in stock on July 23, but cuts off before giving the surrounding details. That incomplete passage does not support a fuller account of the trade, its timing relative to government information, or any legal finding.
The historical argument in the source points to the Constitution’s separation of powers and its two emoluments clauses, in Article I, Section 9, and Article II, Section 1. It says the framers feared that gifts or other benefits could draw public officials away from public duties. Benjamin Franklin’s warning about people pursuing selfish interests is cited as an example of that concern. These constitutional provisions are part of the source’s case for scrutiny, not a report of a newly adopted enforcement measure.
The practical impact described is limited to the financial relationships and election calendar in the excerpt. It reports no new fees, forms, compliance deadlines, or enforcement process, and it does not say that an agency has opened an investigation. The directly affected parties named include the president, his family and business partners, investors in the cryptocurrency products, and public agencies whose decisions touch the relevant industries. The excerpt also says small investors who bought the memecoin were hurt by its decline, though it gives no count of investors or total losses.
The source calls for voters to weigh the issue in the 2026 midterms and 2028 presidential election. Those elections are the next steps identified in the material, not a substitute for legal findings. Any legal questions described in the excerpt remain matters for courts to decide, and the material offers no timetable for such decisions. Careful attention to the election calendar and any court proceedings is necessary to assess the claims and determine whether applicable rules have been followed.
Susan Carter serves as a Senior Correspondent for Just Right News, where she leads the network’s comprehensive coverage of Health, Medicine, and Public Policy. With a career dedicated to dissecting the complexities of the American healthcare system, Susan brings a principled perspective to the most pressing debates of the day. Her reporting is characterized by a commitment to individual liberty, fiscal responsibility, and a healthy skepticism of government overreach, making her a vital voice for audiences seeking clarity in an increasingly regulated landscape.
Raised in Minneapolis, Minnesota, Susan’s professional outlook is deeply informed by the values of the American heartland. Growing up in the Twin Cities, she witnessed firsthand the importance of community-driven solutions and the resilience of the individual. This Midwestern foundation instilled in her a firm belief that the best answers to public policy challenges often come from local innovation and personal responsibility rather than top-down federal mandates. Her background allows her to translate complex legislative jargon into stories that resonate with families who value common sense and local autonomy.
Now based in Baltimore, Maryland, Susan operates from a unique vantage point at the intersection of medical innovation and urban policy. Living and working in a city renowned for its world-class medical institutions and significant public health challenges, she has a front-row seat to the realities of the modern healthcare landscape. Her proximity to these hubs of research and policy allows her to scrutinize how government intervention affects the quality of care and the freedom of medical professionals. In Baltimore, she sees the tangible results of policy decisions, using the city as a lens through which to examine the broader national health debate and the impact of federal spending on local communities.
As the lead for the acclaimed feature series “The Cost of Care,” Susan dives deep into the economic realities facing patients and providers alike. Her work focuses on the necessity of price transparency, the benefits of market competition, and the preservation of the sacred doctor-patient relationship. She is a staunch advocate for the idea that a well-informed public is the best defense against bureaucratic inefficiency. Through this series, she has exposed the hidden drivers of rising medical expenses, always seeking to empower the individual consumer over the massive institution.
Susan’s reporting on public policy is characterized by a commitment to rigorous inquiry and a focus on constitutional limits. Whether she is analyzing new pharmaceutical regulations, investigating the impact of federal health mandates, or exploring the future of medical technology, her goal remains the same: to provide Just Right News audiences with the facts they need to navigate a complex world. By blending her Midwestern sensibilities with the insights gained from her base in Maryland, Susan Carter has become a trusted authority for those who believe that personal freedom and public health are inextricably linked. Her work continues to challenge the status quo, advocating for a system that respects the taxpayer and prioritizes the patient.